Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer

British Journal of Cancer

Volumn 82, Issue 11, 2000, Pages 1776-1782

  Propper, D J ^a   Levitt, N C ^a   O'Byrne, K ^a   Braybrooke, J P ^a   Talbot, D C ^a   Ganesan, T S ^a   Thompson, C H ^b   Rajagopalan, B ^b   Littlewood, T J ^b   Dixon, R M ^b   Harris, A L ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

ATP; Bioreductive agent potentiation; MRS

Indexed keywords

DEXAMETHASONE; HEMOGLOBIN; METOCLOPRAMIDE; MITOMYCIN C; OXYHEMOGLOBIN; VELARESOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPOXEMIA; INJECTION PAIN; MALE; NAUSEA; OXYGEN SATURATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT FAILURE; VOMITING;

EID: 0034035507     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1138     Document Type: Article

References (32)

1. Adams GE, Barnes, DW du Boulay C, Loutit JF, Cole S, Sheldon PW, Stratford IJ, van den Aardweg GJ, Hopewell JW, While RD, Kneen G, Nethersell ABW and Edwards JC (1986) Induction of hypoxia in normal and malignant tissues by changing the oxygen affinity of hemoglobin: implications for therapy. Int J Radiat Oncol Biol Phys 12: 1299-1302
2. Adams GE, Hasan NM and Joiner MC (1997) The Klaas Breur Lecture. Radiation, hypoxia and genetic stimulation: implications for future therapies. Radiother Oncol 44: 101-109
3. Beddell CR, Goodford PJ, Kneen G, White RD, Wilkinson S and Wootton R (1984) Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes. Br J Pharmacol 82: 397-407
4. Brizel DM, Sibley GS, Prosnitz LR, Scher RL and Dewhirst MW (1997) Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38: 285-289
5. Brown JM (1998) The potential benefit of hypoxic cytotoxins in radio-oncology. In: Blood Perfusion and Micro-environment in Human Tumours: Implications for Clinical Radio-oncology, Brady LW and Heilmann H-P (eds), pp. 219-229. Springer-Verlag: Berlin
6. Buroker T, Kim PN, Groppe C, McCracken J, O'Bryan R, Panettiere F, Coltman C, Bottomley R, Wilson H, Bonnet J, Thigpen T, Vaitkevicius VK, Hoogstraten B and Heilbrun L (1978) 5-FU infusion with mitomycin C versus 5-FU infusion with methyl-CCNU in the treatment of advanced colon cancer: a Southwest Oncology Group Study. Cancer 42: 1228-1233
7. Cole S and Robbins L (1989) Manipulation of oxygenation in a human tumour xenograft with BW12C or hydralazine: effects on responses to radiation and to the bioreductive cytotoxicity of misonidazole or RSU-1069. Radiother Oncol 16: 235-243
8. Dennis IF, Ramsay JR, Workman P and Bleehen NM (1993) Pharmacokinetics of BW12C and mitomycin C, given in combination in a phase 1 study in patients with advanced gastrointestinal cancer. Cancer Chemother Pharmacol 32: 67-72
9. Dixon RM (1996) Phosphatidylethanolamine synthesis in the normal and lymphomatous mouse liver: a 13C NMR study. Anticancer Res 16: 1351-1356
10. Dixon RM, Angus PW, Rajagopalan B and Radda GK (1991) Abnormal phosphomonoester signals in 31P MR spectra from patients with hepatic lymphoma. A possible marker of liver infiltration and response to chemotherapy. Br J Cancer 63: 953-958
11. Dixon RM, Angus PW, Rajagopalan B and Radda GK (1992) 31P magnetic resonance spectroscopy detects a functional abnormality in liver metabolism after acetaminophen poisoning. Hepatology 16: 943-948
12. Falk SJ, Ramsay JR, Ward R, Miles K, Dixon AK and Bleehen NM (1994) BW12C perturbs normal and tumour tissue oxygenation and blood flow in man. Radiother Oncol 32: 210-217
13. Fitzharris P McLean AE, Sparks RG, Weatherley BC, White RD and Wooton R. (1985) The effects in volunteers of BW12C, a compound designed to left-shift the blood-oxygen saturation curve. Br J Clin Pharmacol 19: 471-481
14. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R and Lewis AD (1996) Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. Journal of the National Cancer Institute 88: 259-269
15. Gehan A (1961) The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13: 346-353
16. Hartmann JT, Harstrick A, Daikeler T, Kolimannsberger C, Muller C, Seeber S, Kanz L and Bokemeyer C (1998) Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. Anticancer Drugs 9: 427-431
17. Hochachka PW, Buck LT, Doll CJ and Land SC (1996) Unifying theory of hypoxia tolerance: molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Proc Natl Acad Sci USA 93: 9493-9498.
18. Honess DJ, Hu, DE and Bleehen, NM (1991) BW12C: effects on tumour hypoxia. tumour thermosensitivity and relative tumour and normal tissue perfusion in C3H mice. Br J Cancer 64: 715-722.
19. Honess DJ, Nethersell AB and Bleehen NM (1992) In vitro and in vivo studies using BW12C: toxicity, haemoglobin modification and effects on the radiosensitivity of normal marrow and RIF-1 tumours in mice. Int J Radiat Biol 61: 83-94.
20. Lehmann H and Huntsman RG (1966) Man's Haemoglobins. North Holland Publishing Company, Amsterdam.
21. Migeod F, Gerlach D, Kress M, Hoffmann W, Farroukh R and Seeber S (1988) Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C. Onkologie 2: 14-20.
22. Mikami K, Naito M, Tomida A, Yamada M, Sirakusa T and Tsuruo T (1996) DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines. Cancer Research 56: 2823-2826.
23. Negendank W (1992) Studies of human tumors by MRS: a review. NMR Biomed 5: 303-324.
24. Patterson LH (1993) Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metastasis Rev 12: 119-134.
25. Philip PA, Thompson CH, Carmichael J, Rea D, Mitchell K, Taylor DJ, Stuart NS, Dennis I, Rajagopalan B, Ganesan T, Radda GK and Harris AL (1993) A phase I study of the left-shifting agent BW12C79 plus mitomycin C and the effect on the skeletal muscle metabolism using 31P magnetic resonance spectroscopy. Cancer Res 53: 5649-5653.
26. Plumb JA and Workman P (1994) Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer 56: 134-139.
27. Richards F, Case LD, While DR, Muss HB, Spurr CL, Jackson DV, Cooper MR, Zekan P, Cruz J, Stuart JJ and et al. (1986) Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the Piedmont Oncology Association. J Clin Oncol 4: 565-570.
28. Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, Prendiville J, Watson M, Massey A, Popescu R and Oates J ( 1997) A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 8: 995-1001.
29. Ruiz-Cabello J and Cohen JS (1992) Phospholipid metabolites as indicators of cancer cell function. NMR Biomed 5: 226-233.
30. Sartorelli AC, Hodnick WF, Belcourt MF, Tomasz M, Haffty B, Fischer JJ and Rockwell S (1994) Mitomycin C: a prototype Bioreductive agent. Oncol Res 6: 501-508.
31. Workman P and Stratford IJ (1993) The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev 12; 73-82.
32. Zaniboni A, Meriggi F, Alghisi A, Mutli S, Distefano L, Rizzi A, Bettini L, Simoncini E, Marpicati P, Montini E and et al. (1995) Mitomycin-C and Ionidamine as second-line therapy for colorectal cancer: a phase II study. Tumori 81: 435-137.